Specify a stock or a cryptocurrency in the search bar to get a summary
Galapagos N.V.
GLPGGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. Address: Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
Analytics
WallStreet Target Price
34.62 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GLPG
Dividend Analytics GLPG
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GLPG
Stock Valuation GLPG
Financials GLPG
Results | 2019 | Dynamics |